Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SAB-142Positive

AI Analysis

Summary

Breakthrough T1D awarded a grant to support the PRISE-hATG study of SAB-142 in Stage 3 Type 1 Diabetes. This funding provides support for Sab Biotherapeutics' clinical development program.

Clinical Trial Data

Outcome Details

Grant awarded to support PRISE-hATG study

Importance:4/10

Sentiment:

0.60

grant fundingtype 1 diabetesclinical developmentSAB-142

Related Companies

$SABS

Read the original article

Published by yahoo_finance on July 7, 2026 12:00 PM

Read Original